Skip to main navigation Skip to search Skip to main content

Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial

  • German Pancreatic Cancer Working Group (AIO-PAK) and NEOLAP investigators
  • University Hospital Würzburg
  • University Hospital of Essen
  • University Medical Center Hamburg-Eppendorf
  • Paracelsus Medical University
  • SLK-Clinics Heilbronn
  • University Hospital of Cologne
  • Free University of Berlin
  • München Klinik Bogenhausen
  • Klinikum Weiden
  • Ludwig-Maximilians-Universität München
  • University Medical Center Ulm and Center of Excellence 'Metabolic Disorders'
  • ClinAssess Gesellschaft für klinische Forschung mbH
  • Clinical Research
  • Klinikum Ludwigshafen

Research output: Contribution to journal › Article › peer-review

193 Scopus citations

Fingerprint

Dive into the research topics of 'Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial'. Together they form a unique fingerprint.
Sort by

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science